ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2021
Transcatheter treatment for tricuspid valve disease.
Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 4 syntheses or guidelines pooled it, 291 citations in OpenAlex.
- Right ventricle to pulmonary artery coupling as a prognostic factor in tricuspid regurgitation: A systematic review.ESC heart failure · 2025Pooled it
- Evaluation of tricuspid regurgitation by cardiac magnetic resonance and comparison with echocardiography: a systematic review.The international journal of cardiovascular imaging · 2025Pooled it
- Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Guideline
- Bibliometric analysis of imaging and treatment strategies for severe tricuspid regurgitation from 2015 to 2023.Frontiers in cardiovascular medicine · 2024Pooled it
- Trial
- Transjugular Tricuspid Edge-to-Edge Repair for Hostile Inferior Vena Cava Anatomy.JACC. Case reports · 2026Article
- Personalized tricuspid valve modeling predicts regurgitation biomechanical repair and double‑orifice flow.Physical and engineering sciences in medicine · 2026Article
- Prognostic Value of Right Ventricular Circumferential Strain in Patients Undergoing Isolated Tricuspid Valve Surgery.JACC. Asia · 2026Article
- Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre.European heart journal · 2026Review
- Transcatheter bi-caval valve implantation in a post-pacemaker patient with severe tricuspid regurgitation: A case report.Journal of cardiology cases · 2026Article
- Isolated or concomitant tricuspid valve surgery for massive or torrential tricuspid regurgitation.JTCVS open · 2026Article
- Multimodality echocardiography in structural heart disease: the evolving role of the interventional imager.European heart journal. Imaging methods and practice · 2026Review
- Tricuspid valve disease: updates on diagnostic imaging and intervention.Nature reviews. Cardiology · 2026Review
- Acute mitral regurgitation after transcatheter tricuspid valve replacement - case report.European heart journal. Case reports · 2026Article
- Contemporary insights and evolving clinical pathways in transcatheter tricuspid valve replacement.Herz · 2026Review
- Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes.European heart journal. Cardiovascular pharmacotherapy · 2026Observational
- Screening and Qualification for Transcatheter Tricuspid Valve Interventions-Preliminary Findings from the CAPTURE Pilot Study.Life (Basel, Switzerland) · 2026Article
- Navigating isolated tricuspid regurgitation: A practical guide to perioperative and periprocedural management.JTCVS open · 2026Article
- Comparison of Echocardiographic Right Ventricular-Pulmonary Arterial Coupling Indices in Patients Undergoing Transcatheter Tricuspid Valve Repair.Structural heart : the journal of the Heart Team · 2026Article
- 2025 ESC/EACTS valvular heart disease guidelines: practical updates on mitral and tricuspid regurgitation.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 12 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 4% of subjects aged 75 years or more have clinically relevant tricuspid regurgitation (TR). Primary TR results from anatomical abnormality of the tricuspid valve apparatus and is observed in only 8-10% of the patients with tricuspid valve disease. Secondary TR is more common and arises as a result of annular dilation caused by right ventricular enlargement and dysfunction as a consequence of pulmonary hypertension, often caused by left-sided heart disease or atrial fibrillation. Irrespective of its aetiology, TR leads to volume overload and increased wall stress, both of which negatively contribute to detrimental remodelling and worsening TR. This vicious circle translates into impaired survival and increased heart failure symptoms in patients with and without reduced left ventricular ejection fraction. Interventions to correct TR are underutilised in daily clinical practice owing to increased surgical risk and late patient presentation. The recently introduced transcatheter tricuspid valve interventions aim to address this unmet need. Dedicated expertise and an interdisciplinary Heart Team evaluation are essential to integrate these new techniques successfully and select patients. The present article proposes a standardised approach to evaluate patients with TR who may be candidates for transcatheter interventions. In addition, a state-of-the-art review of the available transcatheter therapies, the main criteria for patient and device selection, and information concerning the remaining uncertainties are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.